The Value of mNGS in Diagnosis of Pulmonary Infection
Sponsored by Yunfeng Hou
About this trial
Last updated 2 years ago
Study ID
WJP2023
Status
Unknown
Type
Observational
Placebo
No
Accepting
18 to 85 Years
All Sexes
Trial Timing
Ended 8 months ago
What is this trial about?
Retrospective analysis of clinical data from 50 hospital-admitted patients with suspected pulmonary infection (as judged by clinical manifestations and imaging findings) was performed on study participants who had collected two different samples of alveolar lavage fluid (BALF) and sputum and underwent metagenomic next generation sequencing (mNGS) and routine pathogen detection, respectively. The positive rate of pathogen detection and the consistency of pathogen detection results of the two detection methods were compared to evaluate the clinical manifestation and role of mNGS in pathogen diagnosis.
What are the participation requirements?
Inclusion Criteria
Inclusion criteria: Patients meeting diagnostic criteria for pulmonary infection between January 1, 2020 and October 31, 2023. Patients with pulmonary infection were diagnosed with new or worsening focal or diffuse infiltrating lesions on chest CT accompanied by at least one of the following four pneumonic-related clinical manifestations: (1) Recent cough, sputum, or aggravation of existing respiratory symptoms with or without purulent sputum, chest pain, dyspnea, and hemoptysis; ② Heat, T≥38℃; ③ Signs of lung consolidation and/or smell and moist rales; ④ Peripheral blood white blood cell count > 10*109/L or < 4*109/L.
Exclusion criteria: ① The patient did not undergo bronchoscopy; Absence of clinical or laboratory data.
Exclusion Criteria